Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

TiGenix Rheumatoid Arthritis Trial Moves to Randomized Stage

Oct. 25 (Bloomberg) -- TiGenix NV got approval from the independent Safety Monitoring Board to move its Phase IIa clinical trial in rheumatoid arthritis into randomized recruitment.

“This decision is based on the analysis of the safety data from patients treated in the study’s first cohort,” TiGenix said today in an e-mailed statement.

Link to Company News:{TIG BB <Equity> CN <GO>}

To contact the editor responsible for this story: Andrew Clapham at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.